Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Objective:To analyze the effects of various factors on the clinical outcome of artificial insemination with donor sperm (AID) under natural cycles.Methods:A total of 16 458 natural cycles with donor sperm were analyzed from January 2011 to December 2018 in Reproductive Center of Guangdong Province Family Planning Science and Technology Research Institute. The relationship between the clinical outcome and the factors such as the women's character, donor sperm quality and cycle related factors with χ 2 and multiple factor generalized estimating equation. Results:Many factors such as women's age ≤ 30 years ( OR=1.865, P<0.001), the woman's age from 31 to 35 years ( OR=1.215, P<0.001), duration of infertility≤5 ( OR=1.139, P=0.007), day 3 luteining hormone (LH) level>8.10 IU/L ( OR=1.309, P=0.022), day 3 estrogen level≤77.10 pmol/L ( OR=1.301, P=0.012), day 3 estrogen level from 77.11 pmol/L to 293.60 pmol/L ( OR=1.099, P=0.044), one dominant follicle per cycle ( OR=1.473, P=0.038), cervical mucus score ≥10 ( OR=1.256, P=0.026), A type endometrium ( OR=1.114, P=0.005), urinary LH strong positive ( OR=1.171, P=0.002), sperm activity ratio more than 54% after thawing ( OR=1.142, P=0.002), progressively motile sperm number ≥ 35×10 6 after thawing ( OR=1.217, P=0.001) and double inseminations per cycle ( OR=1.376, P=0.001) significantly affected the pregnancy rates of AID women under natural cycles. Conclusion:Many factors such as the woman's age, duration of infertility, day 3 LH level, day 3 estrogen level, dominant follicle number per cycle, cervical mucus score, endometrial type, sperm activity ratio after thawing, progressively motile sperm number and insemination times per cycle can affect the women’s pregnancy rate under AID natural cycles.

Objective:To analyze the effects of various factors on the clinical outcome of artificial insemination with donor sperm (AID) under natural cycles.Methods:A total of 16 458 natural cycles with donor sperm were analyzed from January 2011 to December 2018 in Reproductive Center of Guangdong Province Family Planning Science and Technology Research Institute. The relationship between the clinical outcome and the factors such as the women's character, donor sperm quality and cycle related factors with χ 2 and multiple factor generalized estimating equation. Results:Many factors such as women's age ≤ 30 years ( OR=1.865, P<0.001), the woman's age from 31 to 35 years ( OR=1.215, P<0.001), duration of infertility≤5 ( OR=1.139, P=0.007), day 3 luteining hormone (LH) level>8.10 IU/L ( OR=1.309, P=0.022), day 3 estrogen level≤77.10 pmol/L ( OR=1.301, P=0.012), day 3 estrogen level from 77.11 pmol/L to 293.60 pmol/L ( OR=1.099, P=0.044), one dominant follicle per cycle ( OR=1.473, P=0.038), cervical mucus score ≥10 ( OR=1.256, P=0.026), A type endometrium ( OR=1.114, P=0.005), urinary LH strong positive ( OR=1.171, P=0.002), sperm activity ratio more than 54% after thawing ( OR=1.142, P=0.002), progressively motile sperm number ≥ 35×10 6 after thawing ( OR=1.217, P=0.001) and double inseminations per cycle ( OR=1.376, P=0.001) significantly affected the pregnancy rates of AID women under natural cycles. Conclusion:Many factors such as the woman's age, duration of infertility, day 3 LH level, day 3 estrogen level, dominant follicle number per cycle, cervical mucus score, endometrial type, sperm activity ratio after thawing, progressively motile sperm number and insemination times per cycle can affect the women’s pregnancy rate under AID natural cycles.

Background Researches showed that microperimetry can exhibit more tiny visual function damage than conventional perimetry in glaucomatous eyes.However,the study on fixation stability of glaucoma is still rare until now.Objective This study was to compare the correlation between microperimetry Maia (Macular Integrity Assessment) and Humphrey perimetry,and to investigate the changes of the fixation stability in glaucoma patients with hemifield defect.Methods This study proposal was approved by Medical Ethic Committee of Peking University First Hospital.A cross-sectional study was performed under the informed consent of each subject.Thirtyfive eyes of 35 glaucoma patients with hemifield defect by 24-2 Humphrey perimetry were included in Peking University First Hospital from December 2013 to March 2014,and 30 eyes of 30 normal volunteers served as controls.Both Humphery (10-2) and Maia (expert 10-2) were performed on the subjects respectively and the correlation of the results between Humphery (10-2) and Maia (expert 10-2) were analyzed.Then the patients with normal hemifield on Humphrey were assigned to Maia normal group and Maia abnormal group.Fixation stability differences were compared between glaucoma group and normal control group,and between Maia normal group and Maia abnormal group.Results The moderately positive correlation was found in the mean sensitivity between Maia microperimetry and Humphrey perimetry (r=0.403,P =0.001),and the average threshold of Maia microperimetry was moderately positive correlated with the mean defect (MD) of Humphrey perimetry in glaucoma patients (r=0.438,P =0.008).The fixation stability parameter P1 was (67±17)％ and (87±10)％,and that of P2 was (70±16)％ and (88±9)％;the 63％ bicurve elipse area (BCEA) was (5.08±1.55) °2and (2.21±0.60) °2,and the 95％ BCEA was (14.74± 6.04) °2 and (2.86 ± 1.17)°2 in the glaucoma group and normal control group,respectively,showing significant decreases of P1 and P2 and increases of 63％ BCEA and 95％ BCEA in the glaucoma group compared with the normalcontrol group (t=-5.604,-4.831,9.885,11.086,all at P=0.000).In Maia normal group and Maia abnormal group,the P1 was (79±8)％ and (63±17)％,the P2 was (81±10)％ and (67±16)％,the 63％ BCEA was (3.19±0.65)°2 and (5.70±1.22)°2 and the 95％ BCEA was (9.10±2.60)°2 and (19.35±5.01)°2,respectively.Compared with the Maia normal group,the P1 and P2 were significantly lower,and 63％ BCEA and 95 ％ BCEA were higher in the Maia abnormal group (t=-2.468,P=0.019;t=-2.371,P=0.024;t =5.514,P=0.000;t=5.575,P=0.000).Conclusions Maia microperimetry and Humphrey perimetry yield a good correlation for glaucomatous macular function examination.In addition,Maia microperimetry showed that fixation stability decreased in glaucoma patients with hemifield defect.

Objective To study the effect of stanozolol and shenqi injection used in comprehensive treatment of late stage cancer.Methods 158 late stage cancer patients,all treated only by rountine method and supportive treatment were randomly divided into 2 groups.And at the same time,79 patients in the treatment group were treated with stanozolol,2mg,po,tid,and shenqi injection 250ml,ivdrip,qd for nine weeks.All patients were recorded weight and hematology biochemical indicator.Results The treatment group surpasses the control group obviously (P＜0.01 ).Conclusion Stanozolol and shenqi injection can improve quality of life of late stage cancer patients and reduce dyscrasia syndrome.

0.05). The core temperature, levels of TNF-?,IL-6 and IL-8 were lower at t2 and t3 in group Ⅱ than those in group Ⅰ (P